TRIANA Biomedicines

Unlocking the full potential of molecular glues to develop precision medicines and transform patient lives

TRIANA Biomedicines was founded in 2022, is headquartered in Lexington, United States, lists 11–50 employees, and has $230.0M in recorded funding across 2 rounds.

Employees
11–50
Founded
2022
Business Model
B2B
Total Funding
$230.0M
Last Round
$120.0M Series BDec 2025
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 2 funding rounds and 11 investors for this company. The full record is or through the API.

About

TRIANA Biomedicines is a venture-backed biopharmaceutical company pioneering the discovery and development of molecular glue therapeutics to treat cancers and other diseases with historically undruggable targets. Founded in 2022 and headquartered in Lexington, Massachusetts, TRIANA uses a proprietary protein:protein pairing engine and target-first methodology to identify small molecules that promote interactions between two proteins, enabling the ubiquitin-proteasome system to degrade disease-causing proteins. The company's initial focus is targeted protein degradation in oncology, including ALK-positive non-small cell lung cancer (NSCLC), with a pipeline designed to address targets inadequately served by existing therapies. TRIANA raised a $120M Series B in December 2025, bringing total funding to $230M, to advance its molecular glue degrader pipeline toward clinical development.

Summary

TRIANA Biomedicines is a Biotech company based in Lexington, United States, founded in 2022. It lists 11–50 employees. It has raised $230.0M in total across 2 rounds, most recently a $120.0M Series B round in Dec 2025. Investors include Ascenta Capital, Lightspeed Venture Partners and Pfizer Ventures.

Tech & App Stack

1 technology or app tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series BSeries BDec 2025
$120.0M

Sign up to see all 2 events

Funding: Series A through Series B. Amounts, valuations, and investors where available.

Investors

Similar Companies

Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

TRIANA Biomedicines on Indexed.vc
<a href="https://indexed.vc/companies/triana-biomedicines"><img src="https://indexed.vc/api/badge/company/triana-biomedicines" alt="TRIANA Biomedicines on Indexed.vc" width="260" height="76" /></a>